Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALI-2
2024-516232-10-00Phase 4Authorised
- Sponsor
- CHU Nîmes
- Start
- Jul 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 19
01
Overview
Phase 4, open-label, single-arm trial of piperacillin + tazobactam, ertapenem, aztreonam, meropenem, meropenem + vaborbactam and 34 more in bacterial disease and Infection, sponsored by CHU Nîmes. Primary endpoint: Antibiotic PK/PD target attainment. Planned start Jul 2026; status: authorised.
02
Drugs
piperacillin + tazobactamertapenemaztreonammeropenemmeropenem + vaborbactam
03
Conditions
bacterial diseaseInfection
Beyond the preview
Go deeper on 2024-516232-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516232-10-00.